Go Pro
→ Read now. Do not delete. You’ve been warned. (From Porter & Company) (Ad)tc pixel Free RBOT Stock Alerts

Vicarious Surgical (RBOT) Financials

Vicarious Surgical logo
$0.18 0.00 (0.00%)
As of 07/10/2026 03:24 PM Eastern
Compare
Annual Income Statements for Vicarious Surgical

Annual Income Statements for Vicarious Surgical

This table shows Vicarious Surgical's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -13 -35 5.16 -71 -63 -50
Consolidated Net Income / (Loss)		 -13 -35 5.16 -71 -63 -50
Net Income / (Loss) Continuing Operations		 -13 -35 5.16 -71 -63 -50
Total Pre-Tax Income 		-13 -35 5.16 -71 -63 -50
Total Operating Income		 -13 -38 -80 -81 -67 -50
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 13 38 80 81 67 50
Selling, General & Admin Expense		 2.33 13 30 27 22 15
Marketing Expense		 0.86 2.96 6.46 6.23 4.53 2.17
Research & Development Expense		 9.80 22 44 48 40 34
Other Operating Expenses / (Income)		 - - - - 0.00 -0.94
Total Other Income / (Expense), net		 0.11 3.02 85 9.60 3.33 -0.16
Interest & Investment Income		 0.11 0.02 1.44 4.43 3.29 0.97
Other Income / (Expense), net		 0.00 3.09 84 5.19 0.04 -1.13
Basic Earnings per Share		 ($0.16) ($0.36) $0.04 ($14.60) ($10.74) ($8.19)
Weighted Average Basic Shares Outstanding		 - 120.43M 125.96M 175.75M 5.93M 7.12M
Diluted Earnings per Share		 - - - ($14.60) ($10.74) ($8.19)
Weighted Average Diluted Shares Outstanding		 - 120.43M 125.96M 175.75M 5.93M 7.12M
Weighted Average Basic & Diluted Shares Outstanding		 - 120.43M 125.96M 175.75M 5.93M 7.12M

Quarterly Income Statements for Vicarious Surgical

This table shows Vicarious Surgical's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -16 -13 -17 -15 -17 -14 -15 -13 -11 -11 -7.33
Consolidated Net Income / (Loss)		 -16 -13 -17 -15 -17 -14 -15 -13 -11 -11 -7.33
Net Income / (Loss) Continuing Operations		 -16 -13 -17 -15 -17 -14 -15 -13 -11 -11 -7.33
Total Pre-Tax Income 		-16 -13 -17 -15 -17 -14 -15 -13 -11 -11 -7.33
Total Operating Income		 -21 -16 -16 -18 -18 -15 -16 -14 -12 -9.26 -7.50
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 21 16 16 18 18 15 16 14 12 9.26 7.50
Selling, General & Admin Expense		 6.91 5.87 5.00 5.59 5.75 5.54 5.29 4.12 3.16 2.63 2.12
Marketing Expense		 1.40 1.20 1.14 1.20 1.21 0.98 1.04 0.35 0.35 0.43 0.34
Research & Development Expense		 13 8.47 9.97 11 11 8.46 9.42 9.05 7.99 7.14 5.04
Total Other Income / (Expense), net		 5.65 2.43 -0.89 2.51 0.66 1.05 0.32 0.30 0.45 -1.26 0.17
Interest & Investment Income		 0.95 0.97 0.98 0.92 0.80 0.59 0.45 0.26 0.16 0.11 0.04
Other Income / (Expense), net		 4.70 1.49 -1.87 1.59 -0.14 0.46 -0.13 0.04 0.29 -1.36 0.13
Basic Earnings per Share		 ($3.04) ($0.07) ($2.90) ($2.59) ($2.90) ($2.34) ($2.60) ($2.23) ($1.86) ($1.48) ($1.03)
Weighted Average Basic Shares Outstanding		 174.89M 175.75M 147.22M 5.90M 5.91M 5.93M 5.93M 5.95M 6.55M 7.12M 7.12M
Diluted Earnings per Share		 ($3.04) ($0.07) ($2.90) ($2.59) ($2.90) ($2.34) ($2.60) ($2.23) ($1.86) ($1.48) ($1.03)
Weighted Average Diluted Shares Outstanding		 174.89M 175.75M 147.22M 5.90M 5.91M 5.93M 5.93M 5.95M 6.55M 7.12M 7.12M
Weighted Average Basic & Diluted Shares Outstanding		 174.89M 175.75M 147.22M 5.90M 5.91M 5.93M 5.93M 5.95M 6.55M 7.12M 7.12M

Annual Cash Flow Statements for Vicarious Surgical

This table details how cash moves in and out of Vicarious Surgical's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 15 158 -57 -63 -43 -7.17
Net Cash From Operating Activities		 -12 -33 -61 -62 -50 -45
Net Cash From Continuing Operating Activities		 -12 -33 -61 -62 -50 -45
Net Income / (Loss) Continuing Operations		 -13 -35 5.16 -71 -63 -50
Consolidated Net Income / (Loss)		 -13 -35 5.16 -71 -63 -50
Depreciation Expense		 0.16 0.32 1.11 1.85 2.11 1.43
Amortization Expense		 0.00 0.02 0.08 -1.23 -1.01 -0.19
Non-Cash Adjustments To Reconcile Net Income		 0.45 0.62 -71 8.89 13 8.77
Changes in Operating Assets and Liabilities, net		 0.23 0.96 3.36 -0.75 -0.59 -4.91
Net Cash From Investing Activities		 13 -1.29 -5.35 -46 6.86 32
Net Cash From Continuing Investing Activities		 13 -1.29 -5.35 -46 6.86 32
Purchase of Property, Plant & Equipment		 -0.12 -1.29 -5.35 -1.67 -0.18 -0.13
Purchase of Investments		 - - 0.00 -76 -58 -21
Sale and/or Maturity of Investments		 13 - 0.00 32 65 54
Net Cash From Financing Activities		 14 192 9.15 45 0.01 5.76
Net Cash From Continuing Financing Activities		 14 192 9.15 45 0.01 5.76
Repayment of Debt		 -0.05 -0.20 -1.40 -0.02 0.00 -0.05
Issuance of Debt		 14 1.50 0.00 0.20 0.00 0.58
Issuance of Common Equity		 0.00 190 10 47 0.00 5.17
Other Financing Activities, net		 0.04 0.42 0.84 0.30 0.01 0.07
Cash Interest Paid		 0.00 0.04 0.04 0.00 0.00 0.00

Quarterly Cash Flow Statements for Vicarious Surgical

This table details how cash moves in and out of Vicarious Surgical's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 26 -6.29 -15 -18 -13 2.67 -7.14 1.31 -0.75 -0.60 -1.42
Net Cash From Operating Activities		 -17 -11 -14 -11 -13 -12 -12 -14 -10 -9.31 -6.33
Net Cash From Continuing Operating Activities		 -17 -11 -14 -11 -13 -12 -12 -14 -10 -9.55 -6.33
Net Income / (Loss) Continuing Operations		 -16 -13 -17 -15 -17 -14 -15 -13 -11 -11 -7.33
Consolidated Net Income / (Loss)		 -16 -13 -17 -15 -17 -14 -15 -13 -11 -11 -7.33
Depreciation Expense		 0.45 0.53 0.52 0.54 0.51 0.54 0.37 0.41 0.35 0.29 0.18
Amortization Expense		 -0.54 -0.26 -0.47 -0.14 -0.12 -0.28 -0.05 -0.13 0.00 -0.01 0.01
Non-Cash Adjustments To Reconcile Net Income		 -0.88 1.80 5.17 1.73 2.08 1.54 3.12 2.40 2.25 1.00 1.06
Changes in Operating Assets and Liabilities, net		 -0.61 -0.32 -2.69 2.06 1.93 0.34 0.19 -3.00 -1.78 -0.32 -0.24
Net Cash From Investing Activities		 -0.64 5.05 -0.14 -6.95 -0.49 14 4.61 15 9.69 3.02 5.06
Net Cash From Continuing Investing Activities		 -0.64 5.05 -0.14 -6.95 -0.49 14 4.61 15 9.69 3.02 5.06
Purchase of Property, Plant & Equipment		 -0.12 -1.04 -0.01 -0.01 0.03 -0.20 -0.01 - -0.12 -0.01 -0.01
Purchase of Investments		 -0.53 -13 -19 -19 -14 -5.37 -8.93 -2.08 -3.95 -6.38 -1.22
Sale of Property, Plant & Equipment		 - - - - - - 0.00 - - - 0.13
Sale and/or Maturity of Investments		 - 19 19 12 13 20 14 17 14 9.41 6.15
Net Cash From Financing Activities		 44 0.03 0.00 - - 0.01 0.02 0.02 0.03 5.69 -0.15
Net Cash From Continuing Financing Activities		 44 0.03 0.00 - - 0.01 0.02 0.02 0.03 5.69 -0.15
Repayment of Debt		 - - - - - - 0.00 - - - -0.15
Other Financing Activities, net		 0.01 0.03 0.00 - - 0.01 0.02 0.02 0.03 - 0.00

Annual Balance Sheets for Vicarious Surgical

This table presents Vicarious Surgical's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 18 182 140 120 68 20
Total Current Assets		 17 178 120 101 52 12
Cash & Equivalents		 17 174 116 53 9.74 2.57
Short-Term Investments		 - - 0.00 45 39 7.22
Prepaid Expenses		 0.26 4.87 4.20 2.78 2.60 1.79
Plant, Property, & Equipment, net		 0.45 2.25 6.59 6.40 4.48 1.27
Total Noncurrent Assets		 0.10 1.06 13 13 12 6.73
Other Noncurrent Operating Assets		 0.10 1.06 13 13 12 6.73
Total Liabilities & Shareholders' Equity		 18 182 140 120 68 20
Total Liabilities		 0.94 99 29 22 21 9.74
Total Current Liabilities		 0.81 6.25 8.39 7.28 7.67 3.90
Short-Term Debt		 0.05 0.65 0.02 - 0.00 0.53
Accounts Payable		 0.37 1.50 1.73 1.26 1.17 0.89
Accrued Expenses		 0.39 4.10 5.81 4.98 5.28 1.06
Other Current Liabilities		 - 0.00 0.84 1.05 1.22 1.43
Total Noncurrent Liabilities		 0.12 92 21 15 13 5.84
Capital Lease Obligations		 - 0.00 15 14 13 5.84
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 17 83 111 98 47 9.84
Total Preferred & Common Equity		 17 83 111 98 47 9.84
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 17 83 111 98 47 9.84
Common Stock		 48 150 173 231 243 256
Retained Earnings		 -32 -67 -62 -133 -196 -246
Accumulated Other Comprehensive Income / (Loss)		 - - 0.00 0.01 0.05 0.00

Quarterly Balance Sheets for Vicarious Surgical

This table presents Vicarious Surgical's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 132 105 93 81 55 41 29 13
Total Current Assets		 113 87 76 64 40 26 15 5.15
Cash & Equivalents		 59 38 20 7.07 2.60 3.91 3.16 1.41
Short-Term Investments		 51 46 53 54 35 20 10 2.28
Prepaid Expenses		 3.22 2.99 2.70 3.11 2.29 2.10 1.66 1.47
Plant, Property, & Equipment, net		 5.89 5.89 5.33 4.82 4.11 3.79 3.48 1.09
Total Noncurrent Assets		 13 12 12 12 11 11 11 6.34
Other Noncurrent Operating Assets		 13 12 12 12 11 11 11 6.34
Total Liabilities & Shareholders' Equity		 132 105 93 81 55 41 29 13
Total Liabilities		 24 21 21 23 21 18 15 9.02
Total Current Liabilities		 7.80 5.08 7.18 8.60 7.86 5.10 3.18 3.35
Short-Term Debt		 0.00 1.09 - - - - - 0.37
Accounts Payable		 1.53 1.27 1.36 2.42 1.02 0.72 0.92 1.03
Accrued Expenses		 5.27 2.72 4.70 5.01 5.57 3.07 0.91 0.77
Other Current Liabilities		 1.01 - 1.13 1.17 1.26 1.31 1.36 1.18
Total Noncurrent Liabilities		 16 16 14 14 13 13 12 5.67
Capital Lease Obligations		 14 14 13 13 12 12 12 5.67
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 108 84 72 58 34 23 14 3.57
Total Preferred & Common Equity		 108 84 72 58 34 23 14 3.57
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 108 84 72 58 34 23 14 3.57
Common Stock		 228 234 237 240 245 248 250 257
Retained Earnings		 -120 -150 -165 -182 -211 -225 -236 -253
Accumulated Other Comprehensive Income / (Loss)		 -0.09 -0.04 -0.05 0.12 0.02 0.00 0.01 -0.00

Annual Metrics And Ratios for Vicarious Surgical

This table displays calculated financial ratios and metrics derived from Vicarious Surgical's official financial filings.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 43,125,000.00 237,244,624.00 122,369,823.00 174,889,450.00 - 174,889,450.00
DEI Adjusted Shares Outstanding		 1,437,500.00 7,908,154.00 4,078,994.00 5,829,648.00 - 5,829,648.00
DEI Earnings Per Adjusted Shares Outstanding		 -8.96 -4.45 1.26 -12.19 - -8.61
Growth Metrics		 - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% -171.29% 114.68% -1,565.41% 12.61% 23.69%
EBIT Growth		 0.00% -170.60% 111.16% -2,024.40% 11.88% 23.09%
NOPAT Growth		 0.00% -194.36% -199.29% 29.49% 17.49% 24.83%
Net Income Growth		 0.00% -173.45% 114.65% -1,478.15% 11.04% 20.63%
EPS Growth		 0.00% 0.00% 0.00% 0.00% 26.44% 23.74%
Operating Cash Flow Growth		 0.00% -176.61% -83.83% -1.79% 19.82% 9.77%
Free Cash Flow Firm Growth		 0.00% 0.00% -387.31% 66.25% 28.46% 27.60%
Invested Capital Growth		 0.00% -104,716.47% 110.87% 40.19% -25.11% -36.96%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% -86.72% -3.23% -0.72% 7.28%
EBIT Q/Q Growth		 0.00% 0.00% -89.58% -2.94% -0.70% 7.08%
NOPAT Q/Q Growth		 0.00% 0.00% -3.61% 5.91% 0.84% 10.26%
Net Income Q/Q Growth		 0.00% 0.00% -86.47% -2.79% -1.31% 6.36%
EPS Q/Q Growth		 0.00% 0.00% 0.00% -2.79% -1.51% -0.12%
Operating Cash Flow Q/Q Growth		 0.00% -21.80% -16.47% 10.15% -0.84% 5.21%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 18.06% 4.35% 24.35%
Invested Capital Q/Q Growth		 0.00% 0.00% 609.47% 15.62% 2.67% -47.48%
Profitability Metrics		 - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 99.15% 100.20% 131.49% 94.17% 95.06% 98.10%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -76.40% -70.45% 5.31% -68.01% -87.40% -177.51%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% -1,846.74% -518.94% -363.69% -377.14%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -76.40% -70.45% 5.31% -68.01% -87.40% -177.51%
Return on Equity Simple (ROE_SIMPLE)		 -76.40% -42.37% 4.64% -72.54% -135.39% 0.00%
Net Operating Profit after Tax (NOPAT)		 -9.09 -27 -80 -56 -47 -35
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -22.35% -8.94% 62.32% -15.73% -27.51% -75.89%
Return On Investment Capital (ROIC_SIMPLE)		 - - - -50.53% -78.61% -216.14%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -13 -35 3.92 -75 -67 -51
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -13 -35 5.11 -75 -65 -50
Valuation Ratios		 - - - - - -
Price to Book Value (P/BV)		 18.09 15.39 2.29 19.74 1.67 1.57
Price to Tangible Book Value (P/TBV)		 18.09 15.39 2.29 19.74 1.67 1.57
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 49.34 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 2.03% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 15.80 136.19 4.08 1.88
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 29.97 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 39.03 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 17.78 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - -
Debt to Equity		 0.00 0.02 0.13 0.14 0.27 0.65
Long-Term Debt to Equity		 0.00 0.01 0.13 0.14 0.27 0.59
Financial Leverage		 -1.01 -1.89 -1.41 -0.89 -0.84 -0.71
Leverage Ratio		 1.06 2.00 1.66 1.24 1.30 1.54
Compound Leverage Factor		 1.05 2.00 2.18 1.17 1.23 1.51
Debt to Total Capital		 0.28% 1.57% 11.79% 12.34% 21.20% 39.26%
Short-Term Debt to Total Capital		 0.28% 0.77% 0.01% 0.00% 0.00% 3.24%
Long-Term Debt to Total Capital		 0.00% 0.80% 11.78% 12.34% 21.20% 36.02%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 99.72% 98.43% 88.21% 87.66% 78.80% 60.74%
Debt to EBITDA		 0.00 -0.04 2.91 -0.18 -0.19 -0.13
Net Debt to EBITDA		 1.32 4.95 -19.84 1.13 0.56 0.07
Long-Term Debt to EBITDA		 0.00 -0.02 2.90 -0.18 -0.19 -0.12
Debt to NOPAT		 -0.01 -0.05 -0.19 -0.24 -0.27 -0.18
Net Debt to NOPAT		 1.86 6.44 1.27 1.49 0.78 0.10
Long-Term Debt to NOPAT		 0.00 -0.03 -0.19 -0.24 -0.27 -0.17
Altman Z-Score		 191.80 7.77 5.66 50.29 -4.28 -24.80
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - -
Current Ratio		 21.04 28.56 14.35 13.87 6.74 2.97
Quick Ratio		 20.72 27.78 13.85 13.49 6.40 2.51
Cash Flow Metrics		 - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 62 -179 -60 -43 -31
Operating Cash Flow to CapEx		 -10,031.67% -2,583.24% -1,143.70% -3,730.84% -27,753.33% -34,148.48%
Free Cash Flow to Firm to Interest Expense		 0.00 699.47 -894.29 -2,414.33 0.00 0.00
Operating Cash Flow to Interest Expense		 -4,012.67 -374.13 -306.06 -2,492.20 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -4,052.67 -388.62 -332.82 -2,559.00 0.00 0.00
Efficiency Ratios		 - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - -
Invested Capital		 -0.09 -89 9.69 14 10 6.41
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 -89 99 3.89 -3.41 -3.76
Enterprise Value (EV)		 288 1,107 153 1,849 42 12
Market Capitalization		 305 1,279 254 1,933 78 15
Book Value per Share		 $0.39 $0.70 $0.91 $0.56 $7.87 $1.38
Tangible Book Value per Share		 $0.39 $0.70 $0.91 $0.56 $7.87 $1.38
Total Capital		 17 84 126 112 59 16
Total Debt		 0.05 1.32 15 14 13 6.36
Total Long-Term Debt		 0.00 0.68 15 14 13 5.84
Net Debt		 -17 -172 -101 -84 -37 -3.43
Capital Expenditures (CapEx)		 0.12 1.29 5.35 1.67 0.18 0.13
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.63 -0.73 -4.18 -4.50 -5.07 -1.59
Debt-free Net Working Capital (DFNWC)		 16 173 112 94 44 8.21
Net Working Capital (NWC)		 16 172 112 94 44 7.68
Net Nonoperating Expense (NNE)		 3.79 8.45 -85 15 17 15
Net Nonoperating Obligations (NNO)		 -17 -172 -101 -84 -37 -3.43
Total Depreciation and Amortization (D&A)		 0.16 0.34 1.19 0.62 1.10 1.24
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($0.36) $0.04 ($14.70) ($10.74) ($8.19)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 120.43M 125.96M 5.86M 5.93M 7.12M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 ($10.74) ($8.19)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 120.43M 125.96M 5.86M 5.93M 7.12M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 120.43M 125.96M 5.86M 5.93M 7.12M
Normalized Net Operating Profit after Tax (NOPAT)		 -9.09 -27 -56 -56 -47 -35
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - -
EBIT to Interest Expense		 -4,328.33 -394.81 19.61 -3,019.00 0.00 0.00
NOPAT to Interest Expense		 -3,029.83 -300.63 -400.39 -2,258.65 0.00 0.00
EBIT Less CapEx to Interest Expense		 -4,368.33 -409.29 -7.15 -3,085.80 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -3,069.83 -315.11 -427.15 -2,325.45 0.00 0.00
Payout Ratios		 - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 5.82% -3.97% 0.00% 0.00%

Quarterly Metrics And Ratios for Vicarious Surgical

This table displays calculated financial ratios and metrics derived from Vicarious Surgical's official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 127,304,377.00 174,889,450.00 174,889,450.00 174,889,450.00 174,889,450.00 - 174,889,450.00 174,889,450.00 174,889,450.00 174,889,450.00 174,889,450.00
DEI Adjusted Shares Outstanding		 4,243,479.00 5,829,648.00 5,829,648.00 5,829,648.00 5,829,648.00 - 5,829,648.00 5,829,648.00 5,829,648.00 5,829,648.00 5,829,648.00
DEI Earnings Per Adjusted Shares Outstanding		 -3.70 -2.26 -2.92 -2.61 -2.93 - -2.64 -2.27 -1.90 -1.80 -1.26
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 32.66% -20.47% 36.27% 2.93% -4.58% -3.39% 13.20% 16.11% 37.95% 27.50% 53.84%
EBIT Growth		 33.93% -18.10% 36.69% 1.55% -7.47% -3.31% 11.70% 16.40% 37.32% 26.86% 53.57%
NOPAT Growth		 3.65% 24.59% 27.81% 17.45% 16.85% 3.62% 2.25% 23.68% 35.21% 38.19% 52.36%
Net Income Growth		 36.52% -17.27% 36.85% 0.84% -8.83% -6.22% 9.45% 13.09% 35.30% 24.49% 52.39%
EPS Growth		 36.52% 0.00% 0.00% 0.00% 4.61% -3,242.86% 10.34% 13.90% 35.86% 37.02% 60.38%
Operating Cash Flow Growth		 -24.91% 38.24% 22.14% 26.93% 26.58% -3.68% 18.61% -22.78% 17.53% 21.00% 46.25%
Free Cash Flow Firm Growth		 79.42% 86.95% 35.30% 2.70% 62.96% 52.10% 73.79% 49.25% 2.24% 61.52% 59.60%
Invested Capital Growth		 717.73% 40.19% 204.48% 63.50% -15.66% -25.11% -38.13% -7.10% 23.22% -36.96% -33.81%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -3.31% 17.59% -29.93% 12.24% -11.30% 18.53% -9.07% 15.00% 17.67% 4.82% 30.55%
EBIT Q/Q Growth		 -1.66% 15.58% -27.90% 10.31% -10.98% 18.85% -9.31% 14.91% 16.79% 5.31% 30.61%
NOPAT Q/Q Growth		 0.49% 27.22% -3.65% -9.96% -0.24% 15.64% -5.13% 14.15% 14.91% 19.52% 18.97%
Net Income Q/Q Growth		 -2.41% 16.51% -29.67% 10.56% -12.40% 18.52% -10.54% 14.15% 16.32% 4.91% 30.30%
EPS Q/Q Growth		 0.00% 16.51% -29.67% 10.69% -11.97% 19.31% -10.64% 14.23% 16.59% 20.43% 30.41%
Operating Cash Flow Q/Q Growth		 -14.59% 34.21% -27.16% 23.77% -15.13% 7.10% 0.17% -14.99% 22.67% 11.01% 32.08%
Free Cash Flow Firm Q/Q Growth		 -63.70% 48.34% -42.16% 19.07% 37.68% 33.18% 22.23% -56.70% -20.05% 73.70% 18.34%
Invested Capital Q/Q Growth		 62.31% 15.62% 6.61% -18.28% -16.27% 2.67% -11.93% 22.71% 11.06% -47.48% -7.54%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 99.79% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 94.32% 93.28% 94.58% 94.31% 95.52% 95.91% 97.19% 98.04% 98.59% 99.01% 99.46%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -63.78% -68.01% -71.21% -82.71% -75.30% -87.40% -104.36% -125.63% -148.93% -177.51% -223.75%
Cash Return on Invested Capital (CROIC)		 -627.25% -518.94% -643.23% -567.50% -417.09% -363.69% -348.40% -373.03% -373.83% -377.14% -352.36%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -63.78% -68.01% -71.21% -82.71% -75.30% -87.40% -104.36% -125.63% -148.93% -177.51% -223.75%
Return on Equity Simple (ROE_SIMPLE)		 -64.09% 0.00% -72.79% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -15 -11 -11 -12 -12 -10 -11 -9.46 -8.05 -6.48 -5.25
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -0.73% -2.40% -7.51% -4.37% -6.47% -5.69% -9.24% -10.41% -12.06% -20.19% -18.25%
Return On Investment Capital (ROIC_SIMPLE)		 - -9.73% -11.44% -14.58% -17.56% -17.69% -23.80% -27.08% -31.43% -40.00% -54.65%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -17 -14 -18 -16 -18 -15 -16 -13 -11 -11 -7.37
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -17 -14 -18 -16 -18 -14 -16 -13 -11 -10 -7.18
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 28.73 19.74 15.85 0.48 0.58 1.67 1.14 1.94 2.56 1.57 1.44
Price to Tangible Book Value (P/TBV)		 28.73 19.74 15.85 0.48 0.58 1.67 1.14 1.94 2.56 1.57 1.44
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 255.73 136.19 87.19 0.00 0.00 4.08 1.54 2.96 2.80 1.88 1.26
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.13 0.14 0.17 0.18 0.22 0.27 0.36 0.52 0.82 0.65 1.69
Long-Term Debt to Equity		 0.13 0.14 0.16 0.18 0.22 0.27 0.36 0.52 0.82 0.59 1.59
Financial Leverage		 -0.95 -0.89 -0.89 -0.87 -0.87 -0.84 -0.80 -0.76 -0.69 -0.71 -0.60
Leverage Ratio		 1.30 1.24 1.32 1.34 1.28 1.30 1.36 1.41 1.53 1.54 1.80
Compound Leverage Factor		 1.23 1.16 1.25 1.26 1.23 1.24 1.32 1.39 1.51 1.53 1.79
Debt to Total Capital		 11.53% 12.34% 14.80% 15.52% 18.21% 21.20% 26.43% 34.02% 45.01% 39.26% 62.85%
Short-Term Debt to Total Capital		 0.00% 0.00% 1.10% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 3.24% 3.86%
Long-Term Debt to Total Capital		 11.53% 12.34% 13.69% 15.52% 18.21% 21.20% 26.43% 34.02% 45.01% 36.02% 58.99%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 88.47% 87.66% 85.20% 84.48% 81.79% 78.80% 73.57% 65.98% 54.99% 60.74% 37.15%
Debt to EBITDA		 -0.19 -0.18 -0.23 -0.21 -0.20 -0.19 -0.19 -0.20 -0.21 -0.13 -0.15
Net Debt to EBITDA		 1.33 1.13 1.08 0.94 0.74 0.56 0.40 0.20 0.04 0.07 -0.06
Long-Term Debt to EBITDA		 -0.19 -0.18 -0.21 -0.21 -0.20 -0.19 -0.19 -0.20 -0.21 -0.12 -0.14
Debt to NOPAT		 -0.23 -0.24 -0.28 -0.27 -0.27 -0.27 -0.26 -0.27 -0.30 -0.18 -0.21
Net Debt to NOPAT		 1.60 1.49 1.33 1.21 1.02 0.78 0.54 0.28 0.05 0.10 -0.08
Long-Term Debt to NOPAT		 -0.23 -0.24 -0.26 -0.27 -0.27 -0.27 -0.26 -0.27 -0.30 -0.17 -0.19
Altman Z-Score		 76.18 51.98 35.93 -1.19 -2.18 -1.75 -4.52 -6.66 -10.60 -17.96 -29.61
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 14.53 13.87 17.16 10.57 7.44 6.74 5.05 5.11 4.75 2.97 1.54
Quick Ratio		 14.12 13.49 16.57 10.20 7.07 6.40 4.76 4.70 4.22 2.51 1.10
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -29 -15 -21 -17 -11 -7.08 -5.50 -8.62 -10 -2.72 -2.22
Operating Cash Flow to CapEx		 -14,646.61% -1,095.38% -144,580.00% -183,683.33% 0.00% -6,045.13% -235,360.00% 0.00% -8,943.59% -93,120.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 12 14 14 12 9.90 10 8.96 11 12 6.41 5.93
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 14 3.89 9.72 4.59 -1.84 -3.41 -5.52 -0.84 2.30 -3.76 -3.03
Enterprise Value (EV)		 3,003 1,849 1,262 -25 -14 42 14 33 34 12 7.49
Market Capitalization		 3,099 1,933 1,332 35 34 78 39 45 36 15 5.13
Book Value per Share		 $0.85 $0.56 $0.57 $12.19 $9.80 $7.87 $5.74 $3.87 $2.15 $1.38 $0.50
Tangible Book Value per Share		 $0.85 $0.56 $0.57 $12.19 $9.80 $7.87 $5.74 $3.87 $2.15 $1.38 $0.50
Total Capital		 122 112 99 85 71 59 46 35 26 16 9.61
Total Debt		 14 14 15 13 13 13 12 12 12 6.36 6.04
Total Long-Term Debt		 14 14 14 13 13 13 12 12 12 5.84 5.67
Net Debt		 -96 -84 -70 -60 -48 -37 -25 -12 -1.88 -3.43 2.36
Capital Expenditures (CapEx)		 0.12 1.04 0.01 0.01 -0.03 0.20 0.01 0.00 0.12 0.01 -0.12
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -4.58 -4.50 -1.00 -4.48 -5.49 -5.07 -5.57 -2.99 -1.52 -1.59 -1.51
Debt-free Net Working Capital (DFNWC)		 106 94 83 69 55 44 32 21 12 8.21 2.18
Net Working Capital (NWC)		 106 94 82 69 55 44 32 21 12 7.68 1.81
Net Nonoperating Expense (NNE)		 0.76 2.23 5.72 2.81 4.66 3.44 4.37 3.75 3.01 4.03 2.08
Net Nonoperating Obligations (NNO)		 -96 -84 -70 -60 -48 -37 -25 -12 -1.88 -3.43 2.36
Total Depreciation and Amortization (D&A)		 -0.09 0.26 0.06 0.40 0.39 0.26 0.32 0.29 0.35 0.28 0.19
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($3.00) ($2.10) ($3.00) ($2.59) ($2.90) ($2.34) ($2.60) ($2.23) ($1.86) ($1.48) ($1.03)
Adjusted Weighted Average Basic Shares Outstanding		 5.83M 5.86M 4.91M 5.90M 5.91M 5.93M 5.93M 5.95M 6.55M 7.12M 7.12M
Adjusted Diluted Earnings per Share		 ($3.00) ($2.10) $0.00 $0.00 ($2.90) ($2.34) ($2.60) ($2.23) ($1.86) ($1.48) ($1.03)
Adjusted Weighted Average Diluted Shares Outstanding		 5.83M 5.86M 4.91M 5.90M 5.91M 5.93M 5.93M 5.95M 6.55M 7.12M 7.12M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($2.10) $0.00 $0.00 $0.00 ($2.34) $0.00 $0.00 $0.00 ($1.48) $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 5.83M 5.86M 4.91M 5.90M 5.91M 5.93M 5.93M 5.95M 6.55M 7.12M 7.12M
Normalized Net Operating Profit after Tax (NOPAT)		 -15 -11 -11 -12 -12 -10 -11 -9.46 -8.05 -6.48 -5.25
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -4.52% -3.97% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Vicarious Surgical Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Vicarious Surgical's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Vicarious Surgical's net income appears to be on an upward trend, with a most recent value of -$50.18 million in 2025, rising from -$12.88 million in 2020. The previous period was -$63.22 million in 2024. See Vicarious Surgical's forecast for analyst expectations on what's next for the company.

Vicarious Surgical's total operating income in 2025 was -$50.03 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $50.03 million

Over the last 5 years, Vicarious Surgical's total revenue changed from $0.00 in 2020 to $0.00 in 2025, a change of 0.0%.

Vicarious Surgical's total liabilities were at $9.74 million at the end of 2025, a 53.7% decrease from 2024, and a 941.7% increase since 2020.

In the past 5 years, Vicarious Surgical's cash and equivalents has ranged from $2.57 million in 2025 to $173.51 million in 2021, and is currently $2.57 million as of their latest financial filing in 2025.

Over the last 5 years, Vicarious Surgical's book value per share changed from 0.39 in 2020 to 1.38 in 2025, a change of 253.6%.


Related Companies

Financial statements for NYSE:RBOT last updated on 7/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Ray Dalio: Buy Gold. Get Paid.
Ray Dalio, founder of Bridgewater Associates, is urging investors to hold 15% of their portfolio in gold and c...
Investors Alley | Sponsoredtc pixel
BlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely, LLC | Sponsoredtc pixel
The Starlink of Energy
A portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...
Monument Traders Alliance | Sponsoredtc pixel
Buy the “unseen winner of the AI race” before July 22
Marc Chaikin - the analyst who called Nvidia before a 45,000% surge - says one overlooked AI stock could split...
Chaikin Analytics | Sponsoredtc pixel
Elon’s New Currency (BUY NOW)
Elon Musk is reportedly launching a currency system that analysts say could target a $480 trillion market disr...
InvestorPlace | Sponsoredtc pixel
They told you not to miss this one
The largest companies in the SP 500 are now more overvalued relative to fundamentals than they were at the abs...
Thor Metals | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Simple Options Trading For Beginners' book at no cost - normally $29.97. It ou...
Profits Run | Sponsoredtc pixel